Danske Bank’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$29.5K Hold
100
– – ﹤0.01% 706
2026
Q2
$22.7K Hold
100
– – ﹤0.01% 727
2026
Q1
$17.2K Sell
100
-50,916
-100% -$9.44M ﹤0.01% 743
2025
Q4
$10.2M Buy
51,016
+25,005
+96% +$4.54M 0.02% 445
2025
Q3
$4.07M Sell
26,011
-10,676
-29% -$1.7M 0.01% 553
2025
Q2
$5.57M Buy
36,687
+36,187
+7,237% +$4.83M 0.01% 526
2025
Q1
$75.3K Sell
500
-15,255
-97% -$2.56M ﹤0.01% 953
2024
Q4
$2.91M Buy
15,755
+500
+3% +$96.3K 0.01% 599
2024
Q3
$3M Buy
15,255
+300
+2% +$62.3K 0.01% 608
2024
Q2
$3.09M Sell
14,955
-7,270
-33% -$1.65M 0.01% 597
2024
Q1
$6.02M Buy
+22,225
New +$5.31M 0.02% 537

Other funds holding CRL

Danske Bank's CRL Position: Q3 2026 in Review

Danske Bank held its Charles River Laboratories (CRL) position steady in Q3 2026 at 100 shares worth $29.5K. The position accounts for ﹤0.01% of the portfolio, ranked #706.

Danske Bank first reported a position in CRL in Q1 2024 and has held it in 11 quarters since. The position peaked at $10.2M in Q4 2025. 515 funds tracked by Wall St. Rank hold CRL as of Q3 2026.

  • Danske Bank held 100 shares of Charles River Laboratories worth $29.5K as of Q3 2026.
  • Danske Bank left its Charles River Laboratories share count unchanged in Q3 2026.
  • Charles River Laboratories made up ﹤0.01% of Danske Bank's portfolio in Q3 2026, its #706 holding.
  • Danske Bank first reported a position in Charles River Laboratories in Q1 2024 and has held it in 11 quarters since.
  • Danske Bank's Charles River Laboratories position peaked at $10.2M in Q4 2025.
  • 515 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.

Based on Danske Bank's 13F filing for Q3 2026, filed 9 Nov 2026.